Insmed Incorporated (NASDAQ:INSM) Shares Sold by Algert Global LLC

Algert Global LLC reduced its position in Insmed Incorporated (NASDAQ:INSM - Free Report) by 7.1% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 75,754 shares of the biopharmaceutical company's stock after selling 5,747 shares during the quarter. Algert Global LLC's holdings in Insmed were worth $5,230,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the business. Alyeska Investment Group L.P. lifted its stake in shares of Insmed by 25.2% during the fourth quarter. Alyeska Investment Group L.P. now owns 935,779 shares of the biopharmaceutical company's stock valued at $64,606,000 after acquiring an additional 188,377 shares during the period. Allostery Investments LP acquired a new position in shares of Insmed during the 4th quarter worth approximately $690,000. Mercer Global Advisors Inc. ADV bought a new stake in Insmed in the 4th quarter valued at $227,000. Freestone Grove Partners LP bought a new stake in shares of Insmed during the fourth quarter worth approximately $524,000. Finally, One68 Global Capital LLC acquired a new stake in Insmed in the 4th quarter worth about $345,000.

Insmed Trading Down 0.8 %

Shares of NASDAQ:INSM traded down $0.55 on Friday, reaching $65.08. 2,388,354 shares of the company traded hands, compared to its average volume of 2,322,333. The company has a current ratio of 6.37, a quick ratio of 5.99 and a debt-to-equity ratio of 2.03. Insmed Incorporated has a 52 week low of $21.92 and a 52 week high of $84.91. The business's 50-day simple moving average is $72.37 and its 200 day simple moving average is $73.27. The stock has a market capitalization of $11.83 billion, a P/E ratio of -11.64 and a beta of 0.84.

Insmed (NASDAQ:INSM - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The biopharmaceutical company reported ($1.42) earnings per share for the quarter, missing the consensus estimate of ($1.36) by ($0.06). Insmed had a negative return on equity of 4,773.73% and a negative net margin of 251.24%. The firm had revenue of $92.82 million during the quarter, compared to analysts' expectations of $91.63 million. During the same period in the previous year, the company earned ($1.06) earnings per share. Insmed's revenue for the quarter was up 22.9% on a year-over-year basis. As a group, equities analysts anticipate that Insmed Incorporated will post -4.56 EPS for the current fiscal year.

Insider Transactions at Insmed

In other news, insider Martina M.D. Flammer sold 37,828 shares of the company's stock in a transaction that occurred on Monday, February 10th. The stock was sold at an average price of $78.61, for a total transaction of $2,973,659.08. Following the sale, the insider now directly owns 100,165 shares of the company's stock, valued at $7,873,970.65. This represents a 27.41 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO William Lewis sold 6,830 shares of Insmed stock in a transaction on Thursday, May 1st. The stock was sold at an average price of $72.57, for a total transaction of $495,653.10. Following the transaction, the chief executive officer now directly owns 233,924 shares of the company's stock, valued at $16,975,864.68. The trade was a 2.84 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 182,337 shares of company stock worth $14,284,557 over the last three months. 3.00% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on INSM. Guggenheim reiterated a "buy" rating and set a $101.00 price objective on shares of Insmed in a research report on Tuesday, February 25th. JPMorgan Chase & Co. increased their price target on Insmed from $83.00 to $92.00 and gave the stock an "overweight" rating in a report on Friday, February 7th. Bank of America raised their price target on shares of Insmed from $92.00 to $96.00 and gave the stock a "buy" rating in a report on Thursday, March 20th. UBS Group lowered their target price on Insmed from $110.00 to $109.00 and set a "buy" rating on the stock in a research report on Friday. Finally, Stifel Nicolaus dropped their target price on Insmed from $97.00 to $96.00 and set a "buy" rating on the stock in a report on Friday, February 21st. One investment analyst has rated the stock with a sell rating and sixteen have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $93.93.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.